FGFR-altered urothelial carcinoma in the EV–pembrolizumab era: Rationale and emerging data for upfront triplet strategies

Critical Reviews in Oncology/Hematology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles